Tag: Rezdiffra

According to the manufacturer and regulatory information, Rezdiffra can be taken at any time of day, with or without food. This flexibility is one of the key considerations for patients and healthcare providers when determining the ideal schedule for this new medication used to treat nonalcoholic steatohepatitis (NASH).

According to the [FDA](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash), approximately 6% of U.S. adults are affected by MASH, a serious liver disease that can lead to scarring (fibrosis). Recently, major advances have answered the question: **What is the new medication for liver scarring?** by bringing the first-ever medications specifically for this condition to market, offering new hope for treatment.

According to the drug manufacturer, Rezdiffra is typically a long-term treatment intended for adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced fibrosis. The answer to **how long do you have to take Rezdiffra** is not a fixed timeline but is a personalized decision made in consultation with a liver specialist based on individual response.

Approved by the FDA in March 2024, resmetirom (Rezdiffra) had an initial annual wholesale acquisition cost (WAC) of $47,400. This comprehensive guide will explore **how much does resmetirom cost**, examining the factors that influence its price for patients, including insurance coverage and financial assistance programs.

Rezdiffra (resmetirom) is the first medication approved for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. Understanding what medications should not be taken with Rezdiffra is crucial for preventing potentially harmful drug interactions.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD, affects up to one-third of the global population. While there is no single best tablet to treat all forms of fatty liver, the approach often involves lifestyle changes and targeted medication for specific patient groups and disease stages.

With approximately 25-30% of the U.S. population affected by metabolic dysfunction-associated steatotic liver disease (MASLD), the recent FDA approval of the first medication to address this condition marks a significant breakthrough. Rezdiffra (resmetirom) is the new drug to reverse fatty liver damage, specifically targeting the more severe form known as MASH.

As the first and only FDA-approved medication for MASH, Rezdiffra is available exclusively through a limited specialty pharmacy network, not from standard retail drugstores. This means patients prescribed Rezdiffra must go through a specific process involving their healthcare provider and the manufacturer's patient support program to access their medication.

In March 2024, Rezdiffra (resmetirom) became the first and only FDA-approved medication for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis. The path to accessing this medication involves specific steps, including a diagnosis from a liver specialist, gaining insurance approval, and navigating a specialty pharmacy network to understand **how can I get Rezdiffra**.

In March 2024, Rezdiffra (resmetirom) became the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring. What is Rezdiffra, and how does this groundbreaking medication target liver damage to potentially reverse disease progression?